Name | Gliquidone |
Description | Gliquidone (AR-DF 26) is a potent, second-generation sulfonylurea with antihyperglycemic activity, exhibiting greater binding affinity to SUR1 and increased potency compared to first-generation compounds. Additionally, this agent exerts peroxisome proliferator-activated receptor (PPAR) gamma agonistic activity. |
In vitro | Intraventricular administration of 0.06–16 μg Gliquidone to each mouse counteracts the antinociceptive effects of tramadol, morphine, and methadone. A dose of 6 μg Gliquidone intraventricularly administered to each mouse inhibits the antinociceptive responses induced by subcutaneous injections of 0.125 mg/kg clonidine and 0.30 mg/kg chlorthalidone; however, a 3 μg dose is ineffective. In male Swiss albino mice, intraventricular injections of 0.1–1.0 μg Gliquidone dose-dependently suppress the antinociceptive effects of amitriptyline and chlorphenamine. In diabetic rats, a 10 mg/kg dose of Gliquidone significantly reduces blood pressure, diminishes non-enzymatic glycation, lowers total protein levels in the lens, and notably increases glutathione levels in the lens. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 97 mg/mL (183.8 mM) Ethanol : 6 mg/mL (11.37 mM)
|
Keywords | Inhibitor | inhibit | Gliquidone |
Inhibitors Related | Minoxidil sulfate | Glibenclamide | (±)-Naringenin | Tolbutamide | Tetraethylammonium bromide | Halothane | Butamben | Cloperastine hydrochloride | 2,2,2-Trichloroethanol | Indapamide |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Diabetic Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |